Drug Trial Radar · NCT04333420
Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
Last checked: Nov 19, 2026Latest source record: Jun 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
399
Actual
Start
Mar 31, 2020
Primary completion
Oct 31, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II \& Phase III: This is a pragmatic, adaptive, randomized, multicenter phase II/III study evaluating IFX-1 for the treatment of COVID-19 related severe pneumonia. The study consists of two parts: Phase II, an open-label, randomized, 2-arm phase evaluating best supportive care (BSC) + IFX-1 (Arm A) and BSC alone (Arm B); and Phase III, a double-blind, placebo-controlled, randomized phase comparing standard of care (SOC) + IFX-1 (Arm A) versus SOC + placebo-to-match (Arm B)
Conditions
- Severe COVID-19 Pneumonia
Interventions
IFX-1 + BSCDrug
Phase II study part: IFX-1 + BSC
BSCDrug
Phase II study part: BSC
IFX-1 + SOCDrug
Phase III study part: IFX-1 + SOC
Placebo + SOCDrug
Phase III study part: Placebo + SOC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position at Day 5 (FAS)Time frame: Baseline and Day 5
- Phase III: 28-day All-cause Mortality (FAS)Time frame: Day 28
Locations
48 sites in 9 countries. Site status is shown where the registry gives one.
InflaRx Site #1107
Aalst, Belgium
InflaRx Site #1102
Brussels, Belgium
InflaRx Site #1104
Leuven, Belgium
InflaRx Site #1106
Lodelinsart, Belgium
InflaRx Site #1101
Yvoir, Belgium
InflaRx Site #0301
Belo Horizonte, Brazil
InflaRx Site #0302
Campinas, Brazil
InflaRx Site #0305
Criciúma, Brazil
InflaRx Site #0308
Curitiba, Brazil
InflaRx Site #0304
Porto Alegre, Brazil
InflaRx Site #0303
São José, Brazil
InflaRx Site #0306
São Paulo, Brazil
InflaRx Site #1011
Grenoble, France
InflaRx Site #1005
Nantes, France
InflaRx Site #1009
Nantes, France
InflaRx Site #1003
Nice, France
InflaRx Site #1001
Paris, France
InflaRx Site #1004
Paris, France
InflaRx Site #1006
Paris, France
InflaRx Site #1008
Paris, France
InflaRx Site #1012
Saint-Etienne, France
InflaRx Site #1002
Suresnes, France
InflaRx Site #0201
Aachen, Germany
InflaRx Site #0207
Augsburg, Germany
InflaRx Site #0202
Berlin, Germany
InflaRx Site #0208
Dresden, Germany
InflaRx Site #0204
Essen, Germany
InflaRx Site #0203
Greifswald, Germany
InflaRx Site #0205
Hanover, Germany
InflaRx Site #0206
Jena, Germany
InflaRx Site #0502
Chihuahua City, Mexico
InflaRx Site #0503
Culiacán, Mexico
InflaRx Site #0506
Mérida, Mexico
InflaRx Site #0504
Monterrey, Mexico
InflaRx Site #0501
Nuevo León, Mexico
InflaRx Site #0505
Veracruz, Mexico
InflaRx Site #0101
Amsterdam, Netherlands
InflaRx Site #0103
Amsterdam, Netherlands
InflaRx Site #0106
Eindhoven, Netherlands
InflaRx Site #0104
Enschede, Netherlands
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.